SNDX
Syndax Pharmaceuticals Inc
+0.72 (+4.17%)18.00USD793K成交股數1.6B市值–本益比(近四季)6.4股價營收比+91.8%營收年增(近四季)2026-11-02下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 72.8M+263% | 64.9M+745% | 45.9M+267% | 38.0M+985% | 20.0M | 7.7M | 12.5M | 3.5M | 0.00 | 0.00 | 0.00 | – |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 68.0M | 58.8M | 56.3M | 62.2M | 61.6M | 65.5M | 71.0M | 48.7M | 56.5M | 39.1M | 34.8M | 34.1M |
| 銷售管理費用 | 41.5M | 37.6M | 44.9M | 43.8M | 41.0M | 37.7M | 31.1M | 29.1M | 23.0M | 17.3M | 14.9M | 12.0M |
| 營業利益 | −40.0M-52% | −34.2M-65% | −57.4M-36% | −69.4M-7% | −83.8M+5% | −96.4M+71% | −89.6M+80% | −74.2M+61% | −79.5M | −56.4M | −49.7M | −46.0M |
| 營業利益率 | -54.9% | -52.7% | -125.2% | -182.7% | -417.9% | -1,254.8% | -716.6% | -2,120.5% | – | – | – | – |
| 稅後淨利 | −49.4M-42% | −42.7M-55% | −60.7M-28% | −71.8M+6% | −84.8M+17% | −94.2M+84% | −84.1M+89% | −68.1M+65% | −72.4M | −51.1M | −44.6M | −41.1M |
| 淨利率 | -67.8% | -65.8% | -132.4% | -189.3% | -423.3% | -1,226.7% | -673.0% | -1,944.7% | – | – | – | – |
| 稀釋 EPS | -0.55-44% | -0.48-56% | -0.70-29% | -0.83+4% | -0.98+15% | -1.09+49% | -0.98+53% | -0.80+36% | -0.85 | -0.73 | -0.64 | -0.59 |
| 稀釋股數 | 89.0M | 88.3M | 86.6M | 86.3M | 86.2M | 85.6M | 85.4M | 85.3M | 85.2M | 69.9M | 69.6M | 69.4M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 336M | 131M | 117M | 109M | 154M | 154M | 133M | 105M | 115M | 94.6M | 97.3M | 57.5M |
| 應收帳款 | – | – | – | – | – | 7.6M | – | – | – | – | – | – |
| 存貨 | 33.2M | 34.9M | 25.0M | 17.7M | 4.7M | 366K | – | – | – | – | – | – |
| 總資產 | 704M | 473M | 552M | 596M | 641M | 725M | 426M | 477M | 543M | 399M | 431M | 460M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 689M | 431M | 436M | 439M | 426M | 437M | 59.4M | 42.6M | 51.1M | 40.0M | 31.3M | 24.3M |
| 股東權益 | 15.1M | 41.6M | 115M | 157M | 215M | 288M | 366M | 434M | 492M | 359M | 400M | 436M |
| 負債比 | 97.9% | 91.2% | 79.1% | 73.6% | 66.4% | 60.2% | 13.9% | 8.9% | 9.4% | 10.0% | 7.3% | 5.3% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −50.3M | – | – | −95.2M+14% | – | – | – | −83.5M | – | – | −39.2M |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 172M
| Biopharmaceutical Cancer Therapeutics | 172M | 100.0% | +627.8% |
|---|
產品／服務2025 年度 · 172M
| Net Product Revenues | 125M | 72.4% | +1525.6% |
|---|---|---|---|
| Collaboration Revenue | 42.4M | 24.6% | – |
| Milestone Revenue | 5.1M | 3.0% | -67.9% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 172M | +627.8% | −285M | -165.6% | -3.29 | −323M |
| FY2024 | 23.7M | – | −319M | -1,346.3% | -3.72 | −275M |
| FY2023 | 0.00 | – | −209M | –% | -2.98 | −161M |
| FY2022 | 0.00 | -100.0% | −149M | –% | -2.46 | −134M |
| FY2021 | 140M | +9109.6% | 24.9M | 17.8% | 0.46 | 29.0M |
| FY2020 | 1.5M | 0.0% | −73.2M | -4,822.5% | -1.87 | −71.3M |
| FY2019 | 1.5M | 0.0% | −56.0M | -3,694.6% | -1.84 | – |
| FY2018 | 1.5M | – | −74.0M | -4,875.5% | -2.92 | −68.7M |